Acute therapies drive overall pharma growth in July: Ind-Ra
The segment delivered strong sales growth of 20% YoY
The segment delivered strong sales growth of 20% YoY
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
Subscribe To Our Newsletter & Stay Updated